IL17A and metabolic dysfunction-associated steatohepatitis: Blocking IL-17A and inhibiting Th17 cell differentiation in mice has demonstrated prevention of MASH and hepatocellular carcinoma (HCC), showcasing the therapeutic promise of IL-17A blockers (124).